Inegy

Simvastatin/Ezetimibe, the active ingredient in Inegy, is a statin and cholesterol absorption inhibitor combination presented as a tablet for oral use. It lowers elevated cholesterol levels and is prescribed for adults with primary hypercholesterolemia, mixed dyslipidemia, or familial hypercholesterolemia.

GNH USA supplies Inegy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides reliable global distribution.

Inegy is used to manage lipid disorders by targeting cholesterol synthesis and absorption pathways. - Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. - Mixed dyslipidemia: improves the overall lipid profile, lowering LDL and triglycerides while modestly raising HDL. - Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when statin monotherapy is insufficient.

Inegy may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Gastrointestinal discomfort: nausea, abdominal pain or diarrhea. - Elevated liver enzymes: mild transaminase increase. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with possible renal impairment. - Hepatotoxicity: marked elevation of liver enzymes or hepatitis. - Severe allergic reactions: rash, angioedema, or anaphylaxis.

Before prescribing Inegy, clinicians should consider several precautionary measures to ensure patient safety. - Liver function monitoring: assess baseline transaminases and repeat periodically. - Renal impairment assessment: adjust therapy in severe renal dysfunction. - Drug‑induced myopathy risk: avoid in patients with a history of statin‑related muscle toxicity. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; generally avoided. - Concomitant medications: review for potential interactions, especially CYP3A4 inhibitors. - Store at ambient temperature: keep below 25 °C, in original packaging, protected from moisture and light.

Inegy interacts with several medicines; the significance of each interaction determines clinical management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can markedly increase simvastatin exposure. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Cyclosporine: enhances both simvastatin and ezetimibe plasma levels, increasing toxicity risk. - HIV protease inhibitors: potentiate simvastatin concentrations, leading to serious adverse events.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may require INR monitoring due to altered metabolism. - Digoxin: ezetimibe can increase digoxin levels; monitor for toxicity. - Niacin: combined use may increase risk of muscle‑related side effects. - Fibrates (other than gemfibrozil): may modestly raise myopathy risk; observe symptoms.